GENELUX CORPORATION Increase (Decrease) in Employee Related Liabilities
GENELUX CORPORATION (GNLX) reported Increase (Decrease) in Employee Related Liabilities of -$209.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Cash Flow
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2024-05-09
- GENELUX CORPORATION increase (decrease) in employee related liabilities for the quarter ending 2024-03-31 was -$209.00K, a 460.34% decline year-over-year.
- GENELUX CORPORATION increase (decrease) in employee related liabilities for the quarter ending 2023-12-31 was -$1.98M.
- GENELUX CORPORATION increase (decrease) in employee related liabilities for the quarter ending 2023-09-30 was $1.42M, a 1671.25% increase year-over-year.
- GENELUX CORPORATION increase (decrease) in employee related liabilities for the quarter ending 2023-06-30 was -$226.00K.
- GENELUX CORPORATION increase (decrease) in employee related liabilities for fiscal 2023 was -$735.00K.
- GENELUX CORPORATION increase (decrease) in employee related liabilities for fiscal 2022 was -$3.00K.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2024-03-31 | -$209.00K 10-Q · filed 2024-05-09 | -$2.19M derived: sum of 2 quarters · filed 2024-05-09 | -$776.00K derived: sum of 3 quarters · filed 2024-05-09 | -$1.00M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | -$1.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$567.00K derived: sum of 2 quarters · filed 2024-03-29 | -$793.00K derived: sum of 3 quarters · filed 2024-03-29 | -$735.00K 10-K · filed 2024-03-29 |
| 2023-09-30 | $1.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $1.19M derived: sum of 2 quarters · filed 2023-11-14 | $1.25M 10-Q · filed 2023-11-14 | $1.15M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | -$226.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$168.00K 10-Q · filed 2023-08-14 | -$263.00K derived: sum of 3 quarters · filed 2024-05-09 | -$183.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $58.00K 10-Q · filed 2024-05-09 | -$37.00K derived: sum of 2 quarters · filed 2024-05-09 | $43.00K derived: sum of 3 quarters · filed 2024-05-09 | -$4.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$95.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$15.00K derived: sum of 2 quarters · filed 2024-03-29 | -$62.00K derived: sum of 3 quarters · filed 2024-03-29 | -$3.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $80.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $33.00K derived: sum of 2 quarters · filed 2023-11-14 | $92.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$47.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $12.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $59.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |